Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 0.17
DVA's Cash to Debt is ranked lower than
59% of the 250 Companies
in the Global Medical Care industry.

( Industry Median: 0.28 vs. DVA: 0.17 )
Ranked among companies with meaningful Cash to Debt only.
DVA' s Cash to Debt Range Over the Past 10 Years
Min: 0  Med: 0.12 Max: 5.2
Current: 0.17
0
5.2
Equity to Asset 0.26
DVA's Equity to Asset is ranked lower than
81% of the 248 Companies
in the Global Medical Care industry.

( Industry Median: 0.50 vs. DVA: 0.26 )
Ranked among companies with meaningful Equity to Asset only.
DVA' s Equity to Asset Range Over the Past 10 Years
Min: 0.03  Med: 0.25 Max: 0.62
Current: 0.26
0.03
0.62
Interest Coverage 4.25
DVA's Interest Coverage is ranked lower than
70% of the 212 Companies
in the Global Medical Care industry.

( Industry Median: 7.64 vs. DVA: 4.25 )
Ranked among companies with meaningful Interest Coverage only.
DVA' s Interest Coverage Range Over the Past 10 Years
Min: 2.87  Med: 4.46 Max: N/A
Current: 4.25
F-Score: 7
Z-Score: 2.10
M-Score: -2.70
WACC vs ROIC
6.85%
8.68%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 9/10

vs
industry
vs
history
Operating margin (%) 12.07
DVA's Operating margin (%) is ranked higher than
64% of the 251 Companies
in the Global Medical Care industry.

( Industry Median: 7.23 vs. DVA: 12.07 )
Ranked among companies with meaningful Operating margin (%) only.
DVA' s Operating margin (%) Range Over the Past 10 Years
Min: 8.49  Med: 15.37 Max: 17.15
Current: 12.07
8.49
17.15
Net-margin (%) 4.92
DVA's Net-margin (%) is ranked higher than
51% of the 251 Companies
in the Global Medical Care industry.

( Industry Median: 4.83 vs. DVA: 4.92 )
Ranked among companies with meaningful Net-margin (%) only.
DVA' s Net-margin (%) Range Over the Past 10 Years
Min: 1.96  Med: 6.54 Max: 7.25
Current: 4.92
1.96
7.25
ROE (%) 14.78
DVA's ROE (%) is ranked higher than
69% of the 234 Companies
in the Global Medical Care industry.

( Industry Median: 9.80 vs. DVA: 14.78 )
Ranked among companies with meaningful ROE (%) only.
DVA' s ROE (%) Range Over the Past 10 Years
Min: 5.37  Med: 20.55 Max: 27.64
Current: 14.78
5.37
27.64
ROA (%) 3.83
DVA's ROA (%) is ranked lower than
53% of the 253 Companies
in the Global Medical Care industry.

( Industry Median: 4.14 vs. DVA: 3.83 )
Ranked among companies with meaningful ROA (%) only.
DVA' s ROA (%) Range Over the Past 10 Years
Min: 1.49  Med: 4.86 Max: 5.69
Current: 3.83
1.49
5.69
ROC (Joel Greenblatt) (%) 54.95
DVA's ROC (Joel Greenblatt) (%) is ranked higher than
79% of the 252 Companies
in the Global Medical Care industry.

( Industry Median: 19.67 vs. DVA: 54.95 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
DVA' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 38.04  Med: 56.94 Max: 68.47
Current: 54.95
38.04
68.47
Revenue Growth (3Y)(%) 15.10
DVA's Revenue Growth (3Y)(%) is ranked higher than
76% of the 180 Companies
in the Global Medical Care industry.

( Industry Median: 8.40 vs. DVA: 15.10 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
DVA' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 4.8  Med: 12.7 Max: 39.8
Current: 15.1
4.8
39.8
EBITDA Growth (3Y)(%) -0.60
DVA's EBITDA Growth (3Y)(%) is ranked lower than
74% of the 155 Companies
in the Global Medical Care industry.

( Industry Median: 7.30 vs. DVA: -0.60 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
DVA' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -38.6  Med: 15 Max: 98.2
Current: -0.6
-38.6
98.2
EPS Growth (3Y)(%) -23.00
DVA's EPS Growth (3Y)(%) is ranked lower than
89% of the 132 Companies
in the Global Medical Care industry.

( Industry Median: 6.80 vs. DVA: -23.00 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
DVA' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -29  Med: 14.1 Max: 125.5
Current: -23
-29
125.5
» DVA's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

DVA Guru Trades in Q1 2016

Andreas Halvorsen 1,744,519 sh (New)
Joel Greenblatt 513,100 sh (+69.62%)
Arnold Van Den Berg 328,908 sh (+22.67%)
Jim Simons 1,091,500 sh (+18.11%)
Mario Gabelli 41,563 sh (+4.00%)
Manning & Napier Advisors, Inc 1,911,305 sh (+1.27%)
Warren Buffett 38,565,570 sh (unchged)
Alan Fournier Sold Out
Paul Tudor Jones Sold Out
Ray Dalio 6,600 sh (-79.34%)
» More
Q2 2016

DVA Guru Trades in Q2 2016

Ray Dalio 75,970 sh (+1051.06%)
Andreas Halvorsen 4,611,729 sh (+164.36%)
Jim Simons 1,376,800 sh (+26.14%)
Warren Buffett 38,565,570 sh (unchged)
Joel Greenblatt Sold Out
Mario Gabelli 40,363 sh (-2.89%)
Manning & Napier Advisors, Inc 1,375,595 sh (-28.03%)
Arnold Van Den Berg 79,300 sh (-75.89%)
» More
Q3 2016

DVA Guru Trades in Q3 2016

Joel Greenblatt 45,595 sh (New)
Warren Buffett 38,565,570 sh (unchged)
Andreas Halvorsen Sold Out
Manning & Napier Advisors, Inc 1,354,745 sh (-1.52%)
Arnold Van Den Berg 77,285 sh (-2.54%)
Jim Simons 1,313,500 sh (-4.60%)
Ray Dalio 65,300 sh (-14.05%)
Mario Gabelli 32,613 sh (-19.20%)
» More
Q4 2016

DVA Guru Trades in Q4 2016

Arnold Van Den Berg Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with DVA

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Health Care Providers » Medical Care    NAICS: 621492    SIC: 8092
Compare:NYSE:UHS, OTCPK:BDULF, NYSE:EVHC, NYSE:MD, OTCPK:SKHCF, NAS:WOOF, OTCPK:CAKFY, NYSE:HLS, OTCPK:NMHLY, NAS:ACHC, NYSE:CHE, OTCPK:LTGHY, NAS:LPNT, NAS:SCAI, NYSE:SEM, NYSE:AMN, NYSE:THC, NAS:AMED, NAS:PAHC, NAS:TVTY » details
Traded in other countries:TRL.Germany,
DaVita HealthCare Partners Inc operates kidney dialysis centers and provides related lab services mainly in dialysis centers and in contracted hospitals across the United States. It also operates other ancillary services and strategic initiatives.

DaVita Inc, formerly DaVita HealthCare Partners Inc was incorporated as a Delaware corporation in 1994. It is a provider of dialysis services in the United States for patients suffering from chronic kidney failure, also known as end stage renal disease, or ESRD. The Company also provides administrative and management support services to a medical services joint venture in which the Company owns a 50% interests. As of December 31, 2014, it provided dialysis and administrative services in the U.S. through a network of 2,179 outpatient dialysis centers in 46 states and the District of Columbia, serving a total of approximately 173,000 patients. It also provides acute inpatient dialysis services in approximately 1,000 hospitals and related laboratory services throughout the United States. The United States dialysis and related lab services business. Home-based dialysis services consist of providing equipment and supplies, training, patient monitoring, on-call support services and follow-up assistance to patients who prefer and are able to receive either peritoneal dialysis or hemodialysis treatments in their homes. It provides hospital inpatient hemodialysis services are required for patients with acute kidney failure resulting from trauma, patients in early stages of ESRD and ESRD patients who require hospitalization for other reasons. It owns two separately incorporated, licensed, clinical laboratories, both located in Florida, specializing in ESRD patient testing. These specialized laboratories provide routine laboratory tests covered by the Medicare composite payment rate for dialysis and other physician-prescribed laboratory tests for ESRD patients. The Company's laboratories provide these tests predominantly for its own ESRD patients throughout the United States. It currently operates or provides management and administrative services to 29 outpatient dialysis centers, in which it either owns a non-controlling interest, or is wholly-owned by third parties, under management and administrative services agreements. It continues to face increased competition in the dialysis industry from large and medium-sized providers which compete directly with it for acquisition targets as well as for individual patients.

Top Ranked Articles about DaVita Inc

Another Attempt to Trumpet a Misjudgment Reflections on mistakes made in another investment analysis
Arnold Van Den Berg Sells Coca-Cola, DaVita Largest trades by the investor in the second quarter
Arnold Van Den Berg (Trades, Portfolio) is a value investor and considers himself a student of Benjamin Graham. His investment research seeks to determine the appraised value of a company, often referred to as intrinsic value. Read more...
Low P/S Ratios for DaVita, ConAgra Foods Gurus have been snapping up these stocks
According to GuruFocus' All-in-One Screener, the following are companies with market caps above $5 billion that are trading with low P/S ratios. Read more...
Weekly CEO Sells Highlights Insiders sell INC Research Holdings, DaVita HealthCare Partners, TE Connectivity, Ruckus Wireless
According to GuruFocus Insider Data, these are the largest CEO sales during the past week: INC Research Holdings Inc. (NASDAQ:INCR), DaVita HealthCare Partners Inc. (NYSE:DVA), TE Connectivity Ltd. (NYSE:TEL) and Ruckus Wireless Inc. (NYSE:RKUS). Read more...
Steve Mandel Sells Health Care Stakes Guru sells holdings in Allergan and DaVita HealthCare Partners
Steve Mandel (Trades, Portfolio), founder of Lone Pine Capital, sold out two health care stakes in the fourth quarter. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 18.05
DVA's P/E(ttm) is ranked higher than
72% of the 195 Companies
in the Global Medical Care industry.

( Industry Median: 26.17 vs. DVA: 18.05 )
Ranked among companies with meaningful P/E(ttm) only.
DVA' s P/E(ttm) Range Over the Past 10 Years
Min: 11.6  Med: 18.83 Max: 58.72
Current: 18.05
11.6
58.72
Forward P/E 15.24
DVA's Forward P/E is ranked higher than
70% of the 66 Companies
in the Global Medical Care industry.

( Industry Median: 18.90 vs. DVA: 15.24 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 18.05
DVA's PE(NRI) is ranked higher than
74% of the 195 Companies
in the Global Medical Care industry.

( Industry Median: 26.51 vs. DVA: 18.05 )
Ranked among companies with meaningful PE(NRI) only.
DVA' s PE(NRI) Range Over the Past 10 Years
Min: 11.57  Med: 18.83 Max: 58.72
Current: 18.05
11.57
58.72
Price/Owner Earnings (ttm) 24.31
DVA's Price/Owner Earnings (ttm) is ranked higher than
55% of the 91 Companies
in the Global Medical Care industry.

( Industry Median: 26.85 vs. DVA: 24.31 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
DVA' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 9.66  Med: 16.97 Max: 674.95
Current: 24.31
9.66
674.95
P/B 2.56
DVA's P/B is ranked lower than
54% of the 231 Companies
in the Global Medical Care industry.

( Industry Median: 2.50 vs. DVA: 2.56 )
Ranked among companies with meaningful P/B only.
DVA' s P/B Range Over the Past 10 Years
Min: 2.25  Med: 3.24 Max: 6.46
Current: 2.56
2.25
6.46
P/S 0.91
DVA's P/S is ranked higher than
70% of the 237 Companies
in the Global Medical Care industry.

( Industry Median: 1.45 vs. DVA: 0.91 )
Ranked among companies with meaningful P/S only.
DVA' s P/S Range Over the Past 10 Years
Min: 0.77  Med: 1.17 Max: 1.77
Current: 0.91
0.77
1.77
PFCF 11.88
DVA's PFCF is ranked higher than
82% of the 105 Companies
in the Global Medical Care industry.

( Industry Median: 23.25 vs. DVA: 11.88 )
Ranked among companies with meaningful PFCF only.
DVA' s PFCF Range Over the Past 10 Years
Min: 7.52  Med: 16.21 Max: 42.52
Current: 11.88
7.52
42.52
POCF 6.83
DVA's POCF is ranked higher than
85% of the 153 Companies
in the Global Medical Care industry.

( Industry Median: 14.44 vs. DVA: 6.83 )
Ranked among companies with meaningful POCF only.
DVA' s POCF Range Over the Past 10 Years
Min: 5.22  Med: 9.22 Max: 17.87
Current: 6.83
5.22
17.87
EV-to-EBIT 11.45
DVA's EV-to-EBIT is ranked higher than
86% of the 188 Companies
in the Global Medical Care industry.

( Industry Median: 20.40 vs. DVA: 11.45 )
Ranked among companies with meaningful EV-to-EBIT only.
DVA' s EV-to-EBIT Range Over the Past 10 Years
Min: 8.5  Med: 12.15 Max: 20.4
Current: 11.45
8.5
20.4
EV-to-EBITDA 8.25
DVA's EV-to-EBITDA is ranked higher than
86% of the 201 Companies
in the Global Medical Care industry.

( Industry Median: 14.49 vs. DVA: 8.25 )
Ranked among companies with meaningful EV-to-EBITDA only.
DVA' s EV-to-EBITDA Range Over the Past 10 Years
Min: 6.8  Med: 9.6 Max: 15.4
Current: 8.25
6.8
15.4
PEG 1.97
DVA's PEG is ranked higher than
66% of the 82 Companies
in the Global Medical Care industry.

( Industry Median: 2.76 vs. DVA: 1.97 )
Ranked among companies with meaningful PEG only.
DVA' s PEG Range Over the Past 10 Years
Min: 0.41  Med: 1.45 Max: 5.58
Current: 1.97
0.41
5.58
Shiller P/E 24.35
DVA's Shiller P/E is ranked higher than
62% of the 45 Companies
in the Global Medical Care industry.

( Industry Median: 28.63 vs. DVA: 24.35 )
Ranked among companies with meaningful Shiller P/E only.
DVA' s Shiller P/E Range Over the Past 10 Years
Min: 19.65  Med: 29.69 Max: 54.81
Current: 24.35
19.65
54.81
Current Ratio 1.61
DVA's Current Ratio is ranked higher than
61% of the 252 Companies
in the Global Medical Care industry.

( Industry Median: 1.27 vs. DVA: 1.61 )
Ranked among companies with meaningful Current Ratio only.
DVA' s Current Ratio Range Over the Past 10 Years
Min: 0.39  Med: 1.86 Max: 5.97
Current: 1.61
0.39
5.97
Quick Ratio 1.54
DVA's Quick Ratio is ranked higher than
64% of the 252 Companies
in the Global Medical Care industry.

( Industry Median: 1.14 vs. DVA: 1.54 )
Ranked among companies with meaningful Quick Ratio only.
DVA' s Quick Ratio Range Over the Past 10 Years
Min: 0.37  Med: 1.78 Max: 5.97
Current: 1.54
0.37
5.97
Days Inventory 6.62
DVA's Days Inventory is ranked higher than
79% of the 188 Companies
in the Global Medical Care industry.

( Industry Median: 17.58 vs. DVA: 6.62 )
Ranked among companies with meaningful Days Inventory only.
DVA' s Days Inventory Range Over the Past 10 Years
Min: 3.72  Med: 6 Max: 8.61
Current: 6.62
3.72
8.61
Days Sales Outstanding 46.38
DVA's Days Sales Outstanding is ranked lower than
56% of the 208 Companies
in the Global Medical Care industry.

( Industry Median: 42.10 vs. DVA: 46.38 )
Ranked among companies with meaningful Days Sales Outstanding only.
DVA' s Days Sales Outstanding Range Over the Past 10 Years
Min: 43.53  Med: 63.93 Max: 69.73
Current: 46.38
43.53
69.73
Days Payable 17.38
DVA's Days Payable is ranked lower than
79% of the 160 Companies
in the Global Medical Care industry.

( Industry Median: 38.65 vs. DVA: 17.38 )
Ranked among companies with meaningful Days Payable only.
DVA' s Days Payable Range Over the Past 10 Years
Min: 14.92  Med: 21.11 Max: 27.1
Current: 17.38
14.92
27.1

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio 0.20
DVA's 3-Year Average Share Buyback Ratio is ranked higher than
81% of the 125 Companies
in the Global Medical Care industry.

( Industry Median: -2.50 vs. DVA: 0.20 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
DVA' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -22.6  Med: -0.8 Max: 9.3
Current: 0.2
-22.6
9.3

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 0.79
DVA's Price/Projected FCF is ranked higher than
86% of the 99 Companies
in the Global Medical Care industry.

( Industry Median: 1.72 vs. DVA: 0.79 )
Ranked among companies with meaningful Price/Projected FCF only.
DVA' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.79  Med: 1.15 Max: 6.25
Current: 0.79
0.79
6.25
Price/DCF (Earnings Based) 1.51
DVA's Price/DCF (Earnings Based) is ranked higher than
59% of the 29 Companies
in the Global Medical Care industry.

( Industry Median: 1.65 vs. DVA: 1.51 )
Ranked among companies with meaningful Price/DCF (Earnings Based) only.
N/A
Price/Median PS Value 0.77
DVA's Price/Median PS Value is ranked higher than
78% of the 207 Companies
in the Global Medical Care industry.

( Industry Median: 1.02 vs. DVA: 0.77 )
Ranked among companies with meaningful Price/Median PS Value only.
DVA' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.15  Med: 1.05 Max: 2.21
Current: 0.77
0.15
2.21
Price/Peter Lynch Fair Value 2.48
DVA's Price/Peter Lynch Fair Value is ranked lower than
57% of the 46 Companies
in the Global Medical Care industry.

( Industry Median: 2.34 vs. DVA: 2.48 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
DVA' s Price/Peter Lynch Fair Value Range Over the Past 10 Years
Min: 0.48  Med: 1.28 Max: 8.16
Current: 2.48
0.48
8.16
Earnings Yield (Greenblatt) (%) 8.70
DVA's Earnings Yield (Greenblatt) (%) is ranked higher than
89% of the 238 Companies
in the Global Medical Care industry.

( Industry Median: 3.80 vs. DVA: 8.70 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
DVA' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 4.9  Med: 8.2 Max: 11.8
Current: 8.7
4.9
11.8
Forward Rate of Return (Yacktman) (%) 14.02
DVA's Forward Rate of Return (Yacktman) (%) is ranked higher than
66% of the 114 Companies
in the Global Medical Care industry.

( Industry Median: 9.76 vs. DVA: 14.02 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
DVA' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: 12.3  Med: 20.7 Max: 35.1
Current: 14.02
12.3
35.1

More Statistics

Revenue (TTM) (Mil) $14,563
EPS (TTM) $ 3.46
Beta0.96
Short Percentage of Float3.74%
52-Week Range $54.50 - 78.77
Shares Outstanding (Mil)197.40

Analyst Estimate

Dec16 Dec17 Dec18
Revenue (Mil $) 14,738 15,528
EPS ($) 3.78 4.02 4.58
EPS w/o NRI ($) 3.78 4.02 4.58
EPS Growth Rate
(3Y to 5Y Estimate)
10.51%
Dividends Per Share ($)
» More Articles for DVA

Headlines

Articles On GuruFocus.com
Another Attempt to Trumpet a Mistake Dec 19 2016 
Are Any of Buffett's Holdings Cheap Enough to Buy? Nov 09 2016 
3 Warren Buffett Stocks Fall to 52-Week Lows Oct 28 2016 
Baxter Well Positioned in Fast-Growing Market for Kidney Dialysis Equipment Jul 01 2016 
Arnold Van Den Berg's Largest Buys in 1st Quarter Apr 21 2016 
Weekly CEO Sells Highlights Apr 18 2016 
7 High Quality Guru Stocks Apr 11 2016 
Steve Mandel Sells Health Care Stakes Mar 11 2016 
Undervalued, Predictable Companies Include Monsanto and Western Union Mar 10 2016 
Alan Fournier Makes Modest Reductions in Middleby and Priceline Jan 12 2016 

More From Other Websites
Lifshitz & Miller Law Firm Announces Investigation of DaVita Inc., First NBC Bank Holdings Company,... Jan 18 2017
[$$] Judge Blocks Rule That Could Limit Premium Assistance for Dialysis Patients Jan 12 2017
U.S. judge blocks rule on financial assistance for dialysis patients Jan 12 2017
IMPORTANT INVESTOR ALERT: Goldberg Law PC Announces an Investigation of DaVita Inc. and Advises... Jan 12 2017
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of DaVita Inc. -... Jan 10 2017
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Violations... Jan 10 2017
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of DaVita Inc. (DVA) Jan 10 2017
Amgen Inks Multiple Deals, Offers Update on Repatha Lawsuit Jan 10 2017
DAVITA NOTIFICATION: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of... Jan 09 2017
EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against DaVita Inc. - DVA Jan 09 2017
DaVita Inc. to Present at the 35th Annual J.P. Morgan Healthcare Conference Jan 09 2017
DAVITA INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Termination of a... Jan 09 2017
DaVita Enters Into New Sourcing and Supply Agreement with Amgen and Initiates 2017 Kidney Care... Jan 09 2017
European shares slip, FTSE 100 at record high Jan 09 2017
Dialysis Providers Fall After Disclosing Patient-Care Subpoenas Jan 09 2017
Fresenius Medical, DaVita subpoenaed over premium assistance Jan 07 2017
[$$] Justice Department Probing Premium Assistance for Dialysis Patients Jan 06 2017
[$$] Justice Department Probing Premium Assistance for Dialysis Patients Jan 06 2017
Dialysis Community Seeks Emergency Relief to Block CMS' Unlawful "Midnight" Rule Harming Patients Jan 06 2017
DaVita appoints 'majority diverse' board, names new CFO Jan 05 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)